1.	Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-99-C-0137, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903
2.	Phase I/II Study of Immunization With Autologous In Vitro-Treated Tumor Cells and Dendritic Cells in Combination With Sargramostim (GM-CSF) in Patients With Stage IV or Recurrent Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 16 Sponsor: Other Protocol IDs: HOAG-VACCINE-MEL, NCI-V01-1646, NCT00012064
3.	Phase I/II Study of Immunization With In Vitro-Treated Autologous Tumor Cells and Dendritic Cells With Sargramostim (GM-CSF) in Patients With Stage III or IV or Recurrent Renal Cell Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 16 and over Sponsor: Other Protocol IDs: HOAG-VACCINE-RN, NCI-V01-1647, NCT00014131
4.	Phase I/II Study of Alpha-Fetoprotein Peptide-Pulsed Autologous Dendritic Cells in HLA-A*0201-Positive Patients With Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: UCLA-0001026, NCI-G01-1997, NCT00022334
5.	Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: ERLANGEN-1490, EU-20232, NCT00053391
6.	Phase I/II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Transfected With Autologous Polymerase Chain Reaction-Amplified Tumor RNA in Patients With Stage IV Cutaneous Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: ERLANGEN-DERMA-ER-DC-07, EU-20513, ARGOS-ERLANGEN-DERMA-DC-07, NCT00126685
7.	Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-004, Bukowski-8077, Logan-0506-05, Drabkin-05-0167, White-04-05-01A, Figlin-05-03-099-01, NCT00272649
8.	A Clinical Trial That Looks at the Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients’ Own Immune Cells. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: RDA 0466, NCT00289341
9.	Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: RDA-0537, NCT00345293
10.	Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: 2004-3126, 2004-3126, KUN99-1950, NCT00243594
11.	Phase II Pilot Study of Autologous T-Cell Transplantation With Vaccine-Driven Expansion of Antitumor Effectors After Cytoreductive Therapy in Patients With Metastatic Pediatric Sarcomas Phase: Phase II Type: Treatment Status: Completed Age: 35 and under at initial diagnosis Sponsor: NCI Protocol IDs: NCI-97-C-0052, NCI-T96-0038, T96-0038, NCT00019266
12.	Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed with MART-1 and gp100 Melanoma Antigens in Patients with High Risk Stage III or Completely Resected Metastatic Melanoma (Summary Last Modified 06/2002) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0132, NCT00019890
13.	Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: LAC-USC-10M991, NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102
14.	Phase II Study of APC8015 (Provenge) and Bevacizumab in Patients With Progressive Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: UCSF-0155-01, NCI-2617, UCSF-01554, NCT00027599, 2617
15.	Phase II Study of Autologous Dendritic Cells (DC) Loaded With Autologous Tumor Lysate (DC Vaccine) in Combination With Interleukin-2 and Interferon alfa in Patients With Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DMS-0238, DMS-16090, NCT00085436
16.	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2000-46, NCT00083538
17.	Phase II Study of Multiepitope Autologous Dendritic Cell Vaccine, Trastuzumab (Herceptin®), and Vinorelbine in Women With Locally Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UNC-LCCC-0310, UNC-GCRC-2102-ORC, NCT00088985
18.	Phase II Pilot Randomized Study of Vaccination Comprising Autologous Dendritic Cells Loaded With Autologous Tumor Lysate and Keyhole Limpet Hemocyanin With or Without Non-Myeloablative Fludarabine in Patients With Stage IV Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: STLMC-IMM-03-05, STLMC-L-03-138, NCT00093522
19.	Phase II Study of Adjuvant Vaccine Therapy Comprising Autologous Dendritic Cells Loaded With Allogeneic Non-small Cell Lung Cancer (NSCLC) Cells in Patients With Unresectable Stage IIIA or IIIB, or Resected Stage I-IIIB NSCLC Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI, Other Protocol IDs: UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009, NCT00103116
20.	Phase II Study of MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: NCI Protocol IDs: LAC-USC-10M-03-1, 6262, NCI-6262, LAC-USC-033307, NCT00334776
21.	Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 25 to 75 Sponsor: Other Protocol IDs: 2612-1970, NCT00311272
22.	Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: DMS-0536, NCT00323115
23.	External Beam Radiation With Intratumoral Injection Of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: MCC-14497, BB-IND 10005, IRB 104007, NCT00365872
24.	Phase II Study of Neoadjuvant Dose-Dense Chemotherapy Comprising Paclitaxel, Cyclophosphamide, and Doxorubicin Hydrochloride Followed by Intratumoral Injection of Autologous Dendritic Cells and Surgery With or Without Adjuvant Radiotherapy and/or Hormone Therapy in Women With Stage II or III Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 19 and over Sponsor: NCI Protocol IDs: UNMC-07206, 072-06, NCT00499083
25.	Phase I Study of Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA in Patients With Stage III or IV Renal Cell Carcinoma (Summary Last Modified 11/2001) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DUMC-1862-99-10, DUMC-DORIS-99124, DUMC-GCRC-839, NCI-G00-1787, NCT00005816